Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS
USFDA has granted Zydus an ‘Orphan Drug Designation’ for ZYIL1 to treat patients with Cryopyrin Associated Periodic Syndrome…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.